Literature DB >> 15110980

Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology.

Elizabeth A Giuliano1.   

Abstract

Uveitis is a common sequela to many ocular diseases. Primary treatment goals for uveitis should be to halt inflammation, prevent or control complications caused by inflammation, relieve pain, and preserve vision. Systemic and topical NSAIDs are essential components of the pharmaceutic armamentarium currently employed in the management of ocular inflammation by general practitioners and veterinary ophthalmologists worldwide. NSAIDs effectively prevent intraoperative miosis; control postoperative pain and inflammation after intraocular procedures, thus optimizing surgical outcome; control symptoms of allergic conjunctivitis;alleviate pain from various causes of uveitis; and circumvent some of the unwanted side effects that occur with corticosteroid treatment. Systemic NSAID therapy is necessary to treat posterior uveitis, because therapeutic concentrations cannot be attained in the retina and choroid with topical administration alone, and is warranted when diseases, such as diabetes mellitus or systemic infection, preclude the use of systemic corticosteroids. Risk factors have been identified with systemic and topical administration of NSAIDs. In general, ophthalmic NSAIDs may be used safely with other ophthalmic pharmaceutics; however, concurrent use of drugs known to affect the corneal epithelium adversely, such as gentamicin, may lead to increased corneal penetration of the NSAID. The concurrent use of NSAIDs with topical corticosteroids in the face of significant preexisting corneal inflammation has been identified as a risk factor in precipitating corneal erosions and melts in people and should be undertaken with caution[8]. Clinicians should remain vigilant in their screening of ophthalmic and systemic complications secondary to drug therapy and educate owners accordingly. If a sudden increase in patient ocular pain (as manifested by an increase in blepharospasm, photophobia, ocular discharge, or rubbing)is noted, owners should be instructed to contact their veterinarian promptly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110980     DOI: 10.1016/j.cvsm.2003.12.003

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  6 in total

1.  Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis.

Authors:  J T Toguri; C Lehmann; R B Laprairie; A M Szczesniak; J Zhou; E M Denovan-Wright; M E M Kelly
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

2.  Effect of topical administration of tramadol on corneal wound healing in rats.

Authors:  Ozgun Cuvas Apan; Murat Atabey Ozer; Selcuk Takir; Alparslan Apan; Demet Sengul
Journal:  Int Ophthalmol       Date:  2016-01-28       Impact factor: 2.031

Review 3.  Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases.

Authors:  Marcos L Aranda; María Florencia González Fleitas; Hernán Dieguez; Agustina Iaquinandi; Pablo H Sande; Damián Dorfman; Ruth E Rosenstein
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

4.  Effects of topical flurbiprofen sodium, diclofenac sodium, ketorolac tromethamine and benzalkonium chloride on corneal sensitivity in normal dogs.

Authors:  Raquel de Araújo Cantarella; Juliana Kravetz de Oliveira; Daniel M Dorbandt; Fabiano Montiani-Ferreira
Journal:  Open Vet J       Date:  2017-08-24

Review 5.  Canine and feline uveitis.

Authors:  Wendy M Townsend
Journal:  Vet Clin North Am Small Anim Pract       Date:  2008-03       Impact factor: 2.093

Review 6.  Ocular manifestations of feline viral diseases.

Authors:  Jean Stiles
Journal:  Vet J       Date:  2013-12-01       Impact factor: 2.688

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.